To address this problem, especially for targeted toxins, a combination therapy of immunotoxin plus chemotherapy might improve the clinical outcome combining advantages in drug penetration of chemotherapies with a selective effect on CD133+ cancer stem cells. This evidence concerns the gene PROM1 and cancer.